DOI: https://doi.org/10.22141/2224-0721.4.68.2015.75009

Effect of metformin therapy on the levels of certain adipose tissue hormones and mediators of nonspecific generalized inflammation in patients with newly diagnosed type 2 diabetes

A.M. Urbanovych

Abstract


The aim of the study was to investigate the influence of the drug metformin on the levels of adipose tissue hormones and generalized nonspecific mediators of inflammation in type 2 diabetes. 38 patients with newly diagnosed type 2 diabetes were followed up before and after 12 months of hypoglycemic monotherapy with glucophage. The results indicate that the normalization of carbohydrate metabolism indices and decreased body weight of patients in the presence of the therapy is due not only to direct effects of metformin in improving glucose uptake by peripheral tissues, but by the ability of the drug to modulate adipocytokine secretion.


Keywords


type 2 diabetes mellitus; leptin; resistin; IL-2; IL-6; TNF-α

References


Gomez-Ambrosi J., Frohbeck G. Evidence for the involvement of resistin in inflammation and cardiovascular disease // Diabetes Rev. — 2005. — 1. — 227-234.

Su S.C., Pei D., Hsieh C.H. Circulating proinflammatory cytokines and adiponectin in young men with type 2 diabetes // Acta Diabetol. — 2011. — 48, № 2. — 113-119.

Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance // J. Clin. Invest. — 2006. — 116. — 1793-1801.

Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance // Mol. Med. — 2008. — 14, № 3–4. — 222-231.

Fantuzzi G., Mazzone T. Adipose tissue and atherosclerosis: Exploring the connection // Arterioscler. Thromb. Vasc. Biol. — 2007. — 27. — 996-903.

Nakano K., Hasegawa G., Fukui M. et al. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes // Endocr. J. — 2010. — 57. — 423-430.

Jung H.S., Youn B.S., Cho Y.M. et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus // Metabolism. — 2005. — 54. — 314-420.

Pradhan A.D., Everett B.M., Cook N.R. et al. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial // JAMA. — 2009. — 302. — 1186-1194.

Cicero A.F., Tartagni E., Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice // Arch. Med. Sci. — 2012. — 8. — 907-917.

Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes — scientific review // Journal of the American Medical Association. — 2002. — 287. — 360-372.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. — 1998. — 352. — 854-86.

Sundaresan P., Lykos D., Daher A. et al. Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM // Diabetes Care. — 1997. — 20. — 692-697.

Wulffel M.G., Kooy A., de Zeeuw D. et al. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review // J. Intern. Med. — 2004. — 256. — 1-14.

Glueck C.J., Fontaine R.N., Wang P. et al. Metformin reduces weight, centropedal obesity, insulin, leptin, and low-density lipoprotein cholesterol in non-diabetic, morbidly obese subjects with body mass index greater than 30 // Metabolism. — 2001. — 50. — 856-861.

Fruehwald-Schultes B., Oltmanns K.M., Toschek B. et al. Shortterm treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men // Metabolism. — 2002. — 51. — 531-536.

Урбанович А.М. Рівень лептину в крові хворих на цукровий діабет із різною тривалістю захворювання // Проблеми ендокринної патології. — 2013. — № 4. — 25-30.

Klein J., Westphal S., Kraus D. et al. Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes // J. Endocrinology. — 2004. — 183. — 299-307.

Derosa G., Maffioli P., Salvadeo S.A. et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients // Metabolism. — 2010. — 59. — 887-895.

Kadoglou N.P., Kapelouzou A., Tsanikidis H. et al. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-nave patients with type 2 diabetes // Exp. Clin. Endocrinol. Diabetes. — 2011. — 119. — 63-68.

Adamia N., Virsaladze D., Charkviani N. et al. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes // Georgian Med. News. — 2007. — 145. — 52-55.

Caballero A.E., Delgado A., Aguilar-Salinas C.A. et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial // J. Clin. Endocrinol. Metab. — 2004. — 89. — 3943-3948.

Sheng C.H., Di J., Jin Y. et al. Resistin is expressed in human hepatocytes and induces insulin resistance // Endocrine. — 2008. — 33. — 135-143.

Rajala M.W., Qi Y., Patel H.R. et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting // Diabetes. — 2004. — 53. — 1671-1679.

Calabro P., Golia E., Maddaloni V. et al. Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? // Intern. Emerg. Med. — 2009. — 4. — 25-34.

Karbowska A., Boratynska M., Klinger M. Resistin: a pathogenic factor or a biomarker of metabolic disorders and inflammation? // Postepy Hig. Med. Dosw. — 2009. — 63. — 485-491.

Verma S., Li S.H., Wang C.H. et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction // Circulation. — 2003. — 108. — 736-740.

Calabro P., Chang D.W., Willerson J.T., Yeh E.T. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation // J. Am. Coll. Cardiol. — 2005. — 46. — 1112-1113.

Nagaev I., Bokarewa M., Tarkowski A., Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes // PLoS One. — 2006. — 1. — e31.

Zurawska-Klis M., Kosmalski M., Andrzejczak D., Drzewoski J. Metformin lowers resistin, while insulin decreases C-reactive protein and elevates adiponectin concentrations in patients with type 2 diabetes mellitus // Diabetologia Doswiadczalna i Kliniczna. — 2011. — 11, № 1. — 8-13.

Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor: direct role in obesity — linked insulin resistance // Science. — 1993. — 259. — 87-91.




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2018

 

   Seo анализ сайта